Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells

Anticancer Research

Volumn 21, Issue 4 A, 2001, Pages 2687-2691

  Siegle, I ^a   Fritz, P ^a   McClellan, M ^a   Gutzeit, S ^a   Murdter T E ^a  

^a Institute of Clinical Pharmacology   (Germany)

Author keywords

Cytostatics; Drug combination; Isobologram; Toxicity; Viscum album agglutinin 1 (VAA 1)

Indexed keywords

CISPLATIN; CYCLOHEXIMIDE; DOXORUBICIN; PACLITAXEL; UNCLASSIFIED DRUG; VISCUM ALBUM AGGLUTININ 1; VISCUM ALBUM EXTRACT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL DIVISION; CISPLATIN; CYCLOHEXIMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PLANT PREPARATIONS; PLANT PROTEINS; RICIN; TOXINS, BIOLOGICAL; TUMOR CELLS, CULTURED;

EID: 0035149593     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Treatment of advanced pancreatic cancer with mistletoe: Results of a pilot trial
2. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients
3. Effect of Viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells
4. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients
5. Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: Homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins
6. The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. The RNA N-glycosidase activity of the protein
7. Mistletoe lectins and their A and B chains
8. Mistletoe lectin dissociates into catalytic and binding subunits before translocation across the membrane to the cytoplasm
9. Increased secretion of tumour necrosis factor alpha, interleukin 1 and interleukin 6 by human mononuclear cells exposed to galactoside-specific lectin from clinically applied mistletoe extract
10. Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy
11. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis
12. Induction of apoptosis by mistletoe lectin I and its subunits. No evidence for cytotoxic effects caused by isolated A- and B-chains
13. Worldwide patterns of cancer mortality, 1990-1994
14. Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: Is there any prognostic relevance?
15. Cytotoxicity of mistletoe lectins: Is there a link between in vitro studies and human carcinomas?
16. What is synergy?
17. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice
18. Site-specific mutagenesis of mistletoe lectin: The role of RIP activity in apoptosis
19. Concepts of tumor lectinology
20. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration
21. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin
22. Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells
23. Taxol: A novel investigational antimicrotubule agent
24. Study of protein synthesis in rat liver mitochondria use of cycloheximide
25. Macrophage adherence prevents apoptosis induced by ricin
26. Cell-cycle arrest versus cell death in cancer therapy